CYDY - CytoDyn: Understanding The COVID-19 Opportunity
CytoDyn (CYDY) continues to post impressive Leronlimab press releases that report hopeful accounts that the monoclonal antibody is able to have a positive impact on COVID-19 patient outcomes. It looks as if Leronlimab is able to mitigate the notorious "cytokine storm" that has been the culprit in many COVID-19 deaths. Unfortunately, many investors are having some difficulty understanding how Leronlimab is helping COVID-19 patients and how it differs from other potential therapies.
I intend to provide some basic background on cytokine storms and how Leronlimab has shown its ability to diminish its impact. In addition,